BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19735488)

  • 1. A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses.
    Suessmuth Y; Elliott J; Percy MJ; Inami M; Attal H; Harrison CN; Inokuchi K; McMullin MF; Johnston JA
    Br J Haematol; 2009 Nov; 147(4):450-8. PubMed ID: 19735488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
    Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
    Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
    Fourouclas N; Li J; Gilby DC; Campbell PJ; Beer PA; Boyd EM; Goodeve AC; Bareford D; Harrison CN; Reilly JT; Green AR; Bench AJ
    Haematologica; 2008 Nov; 93(11):1635-44. PubMed ID: 18815196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of serum erythropoietin level and JAK2 V617F allele burden in the diagnosis of polycythaemia vera.
    Ancochea A; Alvarez-Larrán A; Morales-Indiano C; García-Pallarols F; Martínez-Avilés L; Angona A; Senín A; Bellosillo B; Besses C
    Br J Haematol; 2014 Nov; 167(3):411-7. PubMed ID: 25040297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
    Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
    N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels.
    Percy MJ; Scott LM; Erber WN; Harrison CN; Reilly JT; Jones FG; Green AR; McMullin MF
    Haematologica; 2007 Dec; 92(12):1607-14. PubMed ID: 18055983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.
    Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
    Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
    Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.
    Dusa A; Staerk J; Elliott J; Pecquet C; Poirel HA; Johnston JA; Constantinescu SN
    J Biol Chem; 2008 May; 283(19):12941-8. PubMed ID: 18326042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique.
    Leszczynska A; Grzenkowicz-Wydra J; Chmielewska-Gorycka L; Bieniaszewska M; Hellmann A
    Acta Haematol; 2016; 136(2):123-8. PubMed ID: 27410038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycythemia vera: scientific advances and current practice.
    Tefferi A; Spivak JL
    Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation.
    Laubach JP; Fu P; Jiang X; Salter KH; Potti A; Arcasoy MO
    Exp Hematol; 2009 Dec; 37(12):1411-22. PubMed ID: 19815050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel germline JAK2
    Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
    Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.
    Varghese LN; Ungureanu D; Liau NP; Young SN; Laktyushin A; Hammaren H; Lucet IS; Nicola NA; Silvennoinen O; Babon JJ; Murphy JM
    Biochem J; 2014 Mar; 458(2):395-405. PubMed ID: 24354892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.
    Pietra D; Li S; Brisci A; Passamonti F; Rumi E; Theocharides A; Ferrari M; Gisslinger H; Kralovics R; Cremonesi L; Skoda R; Cazzola M
    Blood; 2008 Feb; 111(3):1686-9. PubMed ID: 17984312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
    Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
    PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations.
    Ibrahim IK; Hassan R; Ali EW; Omer A
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):41-44. PubMed ID: 30677867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
    Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
    Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.